Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.37 |
| ▸ | FDPS | P14324 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1200047 | 1.00 | ALOX15 (0.68) | ALOX15ALDH1A1TSHRUSP2TDP1 | |
| SCHEMBL3117924 | 1.00 | ALOX15 (0.68) | ALOX15ALDH1A1TSHRUSP2TDP1 | |
| SCHEMBL1200445 | 0.86 | ALOX15 (0.63) | ALOX15ALDH1A1TSHRUSP2TDP1 | |
| SCHEMBL31562149 | 0.86 | ALOX15 (0.52) | ALOX15ALDH1A1TSHRUSP2TDP1 | |
| SCHEMBL1200446 | 0.86 | ALOX15 (0.63) | ALOX15ALDH1A1TSHRUSP2TDP1 | |
| SCHEMBL3125002 | 0.85 | ALOX15 (0.61) | ALOX15ALDH1A1TSHRUSP2TDP1 | |
| SCHEMBL3108390 | 0.85 | ALOX15 (0.61) | ALOX15ALDH1A1TSHRUSP2TDP1 | |
| SCHEMBL3108399 | 0.85 | ALOX15 (0.61) | ALOX15ALDH1A1TSHRUSP2TDP1 | |
| SCHEMBL1198833 | 0.83 | ALOX15 (0.64) | ALOX15ALDH1A1TSHRUSP2TDP1 | |
| SCHEMBL1198831 | 0.83 | ALOX15 (0.64) | ALOX15ALDH1A1TSHRUSP2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140206670-A1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS | PFIZER INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20120329781-A1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS | PFIZER INC | 2012-12-27 | — | — | US | disclosed |
| US-20110039899-A1 | Gabapentin for the Treatment of Overactive Bladder, Stress Incontinence and BPH | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
| EP-2196201-A2 | Combination of an alpha-2-delta ligand with a pdev inhibitor or a muscarinic antagonist to treat lower urinary tract symptoms | Warner-Lambert Company LLC (US) | 2010-06-16 | — | — | EP | disclosed |
| EP-1572173-B1 | ALPHA-2-DELTA LIGAND TO TREAT LOWER URINARY TRACT SYMPTOMS | WARNER LAMBERT CO (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-2172197-A1 | Octanoic acid derivative to treat fibromyalgia and other pains | Warner-Lambert Company LLC (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20100081718-A1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS | PFIZER INC | 2010-04-01 | — | — | US | disclosed |
| EP-2156863-A2 | Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors | Pfizer Limited (GB) | 2010-02-24 | — | — | EP | disclosed |
| EP-1663398-B1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND SEROTONIN / NORADRENALINE REUPTAKE INHIBITORS | PFIZER LTD (GB) | 2009-11-25 | — | — | EP | disclosed |
| EP-1192125-B9 | MONO-SUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS | WARNER LAMBERT CO (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY SUE (US) | 2003-10-16 | — | — | US | disclosed |
| WO-2003082807-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-09 | — | — | WO | disclosed |
| US-20030181523-A1 | Mono-and disubstituted 3-propyl gamma-aminobutyric acids | BELLIOTTI THOMAS RICHARD (US) | 2003-09-25 | — | — | US | disclosed |
| US-20030176504-A1 | Method of treating tinnitus | DOOLEY DAVID JAMES (US) | 2003-09-18 | — | — | US | disclosed |
| US-6620829-B2 | Administering a therapeutically effective amount of a GABA analog having characteristic of being an inhibitor of cartilage damage, or a pharmaceutically acceptable salt | WARNER-LAMBERT COMPANY | 2003-09-16 | — | — | US | disclosed |
| WO-2003063845-A1 | ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-07 | — | — | WO | disclosed |
| US-20020072533-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2002-06-13 | — | — | US | disclosed |
| EP-1199072-A2 | Method of treating cartilage damage | WARNER-LAMBERT COMPANY (US) | 2002-04-24 | — | — | EP | disclosed |
| EP-1192125-A2 | MONO- AND DISUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000076958-A2 | MONO- AND DISUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039899-A1 | Gabapentin for the Treatment of Overactive Bladder, Stress Incontinence and BPH | GABRB2, GABRB3, GABRB1 | ALOX15 2292/4885ALDH1A1 581/4885TSHR 3117/4885 |
| US-20030176504-A1 | Method of treating tinnitus | ADRA2A, ADRA1A, ADRA1D | ALOX15 2410/4885ALDH1A1 137/4885TSHR 447/4885 |
| US-20020072533-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | ALOX15 1587/4885ALDH1A1 30/4885TSHR 3180/4885 |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | SCN2A, OPRD1, CAMK2A | ALOX15 4434/4885ALDH1A1 3683/4885TSHR 3493/4885 |
| US-20120329781-A1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS | SLC6A2, OPRD1, ADRB2 | ALOX15 3118/4885ALDH1A1 1636/4885TSHR 679/4885 |
| US-20140206670-A1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS | SLC6A2, OPRD1, ADRB2 | ALOX15 3118/4885ALDH1A1 1636/4885TSHR 679/4885 |
| US-20030181523-A1 | Mono-and disubstituted 3-propyl gamma-aminobutyric acids | GABRB1, GABRA1, GABRB3 | ALOX15 412/4885ALDH1A1 311/4885TSHR 1238/4885 |
| US-20100081718-A1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS | SLC6A2, SIGMAR1, OPRL1 | ALOX15 3548/4885ALDH1A1 1455/4885TSHR 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.